Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease.

Glenn M ChertowPriya VartNiels JongsRobert D TotoJose Luis GorrizFan Fan HouJohn J V McMurrayRicardo Correa-RotterPeter RossingC David SjöströmBergur V StefánssonAnna Maria LangkildeDavid C WheelerHiddo J L Heerspinknull null

Published in: Journal of the American Society of Nephrology : JASN (2021)

Among patients with stage 4 CKD and albuminuria, the effects of dapagliflozin were consistent with those observed in the DAPA-CKD trial overall, with no evidence of increased risks.

Keyphrases

chronic kidney disease
end stage renal disease
study protocol
clinical trial
randomized controlled trial
climate change
open label
placebo controlled